Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price was down 8.2% during trading on Wednesday . The company traded as low as $7.12 and last traded at $7.0250. Approximately 68,374 shares changed hands during trading, a decline of 27% from the average daily volume of 93,144 shares. The stock had previously closed at $7.65.

Analyst Ratings Changes

Several research analysts have recently weighed in on GYRE shares. Wall Street Zen cut Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Trading Down 8.0%

The business has a 50-day moving average of $7.97 and a 200 day moving average of $7.78. The firm has a market capitalization of $682.21 million, a P/E ratio of 704.60 and a beta of 1.97.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. The business had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million.

Institutional Trading of Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Gyre Therapeutics by 13.0% in the 4th quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock valued at $2,989,000 after buying an additional 48,602 shares during the last quarter. State Street Corp increased its position in shares of Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Millennium Management LLC bought a new position in Gyre Therapeutics in the 3rd quarter valued at $267,000. Finally, Goldman Sachs Group Inc. increased its position in shares of Gyre Therapeutics by 72.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock valued at $220,000 after purchasing an additional 13,074 shares during the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.